Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010

Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010

Highlights ► A new conjugate vaccine against meningitis A was introduced in Niger in 2010. ► We conducted surveillance of adverse events following immunization. ► We examined the feasibility of implementing the system in a low income country. ► AEFI surveillance did not identify safety concerns with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2012-07, Vol.30 (35), p.5229-5234
Hauptverfasser: Chaibou, Maman S, Bako, Harouna, Salisou, Laouali, Yaméogo, Téné M, Sambo, Mariama, Kim, Sung Hye, Djingarey, Mamoudou H, Zuber, Patrick L.F, Perea, William A, Pezzoli, Lorenzo
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Adverse Drug Reaction Reporting Systems
Adverse events following immunization (AEFI)
Africa
Africa South of the Sahara
Allergy and Immunology
Appropriate technology
Child
Child, Preschool
Emergency medical care
Feasibility Studies
Female
Hospitalization
Humans
Immunization
Laboratories
Low income areas
Malaria
Male
MenAfriVac
Meningitis
Meningitis, Meningococcal - prevention & control
Meningococcal Vaccines - adverse effects
Monitoring
Neisseria meningitidis
Neisseria meningitidis, Serogroup A - pathogenicity
Niger
Niger - epidemiology
Pharmacovigilance
Population Surveillance
Public health
Vaccination - adverse effects
Vaccine safety
Vaccines
Vaccines, Conjugate - adverse effects
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights ► A new conjugate vaccine against meningitis A was introduced in Niger in 2010. ► We conducted surveillance of adverse events following immunization. ► We examined the feasibility of implementing the system in a low income country. ► AEFI surveillance did not identify safety concerns with the vaccine. ► It was feasible to implement the system but results were limited by underreporting. ► Using a simpler predominantly passive system will improve feasibility.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2012.06.006